Literature DB >> 32002657

Correction to: Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus.

Pau Montesinos1,2, Juan Bergua3, Joana Infante4, Jordi Esteve5, José Eduardo Guimaraes6, Jordi Sierra7, Miguel Ángel Sanz8.   

Abstract

After publication of this paper, the authors determined that an additional information in the funding section was missing.

Year:  2020        PMID： 32002657     DOI： 10.1007/s00277-020-03933-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


  1 in total

1.  Myeloablative conditioning with thiotepa-busulfan-fludarabine does not improve the outcome of patients transplanted with active leukemia: final results of the GITMO prospective trial GANDALF-01.

Authors:  Francesca Bonifazi; Chiara Pavoni; Jacopo Peccatori; Fabio Giglio; Mario Arpinati; Alessandro Busca; Paolo Bernasconi; Anna Grassi; Anna Paola Iori; Francesca Patriarca; Lucia Brunello; Carmen Di Grazia; Angelo Michele Carella; Daniela Cilloni; Alessandra Picardi; Anna Proia; Stella Santarone; Roberto Sorasio; Paola Carluccio; Patrizia Chiusolo; Alessandra Cupri; Mario Luppi; Chiara Nozzoli; Donatella Baronciani; Marco Casini; Giovanni Grillo; Maurizio Musso; Francesco Onida; Giulia Palazzo; Matteo Parma; Stefania Tringali; Adriana Vacca; Daniele Vallisa; Nicoletta Sacchi; Elena Oldani; Arianna Masciulli; Angela Gheorghiu; Corrado Girmenia; Massimo Martino; Benedetto Bruno; Alessandro Rambaldi; Fabio Ciceri
Journal:  Bone Marrow Transplant       Date:  2022-04-12       Impact factor: 5.174
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.